CJC-1295 vs Ipamorelin: Which Should You Actually Pick?

CJC-1295 at a glance:

• Drug class: Long-acting GHRH analog (research peptide)
• Route: subcutaneous injection (research use)
• Typical frequency: varies; once weekly (DAC) or daily (no-DAC) in user protocols
• Half-life: approximately 6-8 days (DAC version); ~30 minutes (no-DAC version)

Head-to-head comparisons in this space are useful but easy to overweight. The truth is that most differences shake out to a couple of percentage points of efficacy and a different side-effect distribution. Here's how the two compare.

Mechanism

CJC-1295: CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) version binds albumin to extend its half-life from minutes to days.

Ipamorelin: Ipamorelin is a pentapeptide selective ghrelin/GHS-R1a agonist that stimulates GH release without significantly raising cortisol or prolactin.

For people new to this comparison, the practical takeaway is that the underlying mechanisms are different enough that response can vary.

Dosing & Administration

Effectiveness

CJC-1295: Increased mean GH and IGF-1 levels in early-phase human studies.

Ipamorelin: Selective GH pulse without major effects on other pituitary hormones in early studies.

In head-to-head comparisons (where they exist), the higher-dose newer agents tend to outperform older ones — sometimes meaningfully. Reference trials: Teichman et al for CJC-1295; Raun et al for Ipamorelin.

Side Effects

The two compounds have overlapping side-effect profiles. Common to both:

• injection-site reactions
• transient flushing
• headache

Important risks worth knowing for both:

• fluid retention
• carpal tunnel symptoms
• potential effect on glucose metabolism
• supply-chain contamination from unregulated suppliers

Cost

CJC-1295: pricing varies. Ipamorelin: pricing varies.

Insurance coverage and manufacturer programs change the relative cost picture significantly. See our individual cost guides for CJC-1295 cost and Ipamorelin cost for the latest numbers.

Which Is Right for You?

The practical decision usually comes down to four factors:

1. What's covered by your insurance? Often the deciding factor
2. What does your prescriber have experience with? Familiarity reduces dosing errors
3. How comfortable are you with injections (or oral dosing if applicable)?
4. What's your tolerance for side effects?

If you and your clinician end up split between CJC-1295 and Ipamorelin, either is a defensible choice in most cases.

Switching Between Them

Switching from CJC-1295 to Ipamorelin (or the reverse) is usually straightforward but should be done with clinician guidance — particularly to align dose escalation and avoid GI side effects from re-titration.

Bottom Line

Head-to-head comparisons are useful but rarely decisive. The bigger swing factors are usually outside the comparison itself.

Frequently Asked Questions

Related Reading

• CJC-1295 101: A Plain-English Guide for 2026
• CJC-1295 Side Effects: The Complete List and How to Handle Them
• Does CJC-1295 Really Work? An Evidence-Based Results Review
• The Real CJC-1295 Price Tag in 2026 — With and Without Insurance
• The Honest Guide to MK-677: What Patients and Doctors Actually Say
• Is MK-677 Safe? An Honest Look at the Side-Effect Profile

Sources

• Teichman SL et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295. JCEM 2006;91:799.
• Stanley TL et al. Effects of Tesamorelin on Visceral Fat in HIV-Infected Patients With Lipodystrophy. NEJM 2010;363:2425.
• Nass R et al. Effects of an Oral Ghrelin Mimetic on Body Composition in Healthy Older Adults. Annals of Internal Medicine 2008;149:601.

This page is informational only and is not a personalized recommendation. The right choice depends on your individual situation.